Queensland Health

Extended practice authority

Midwives – version 6

This extended practice authority (**EPA**) has been made under section 232 of the *Medicines and Poisons Act 2019* (Qld) by the Deputy Director-General, Health Workforce Division, as a delegate of the chief executive, Queensland Health. For the purposes of Schedule 7, Part 2 of the Medicines and Poisons (Medicines) Regulation 2021 (Qld) (**MPMR**), the EPA details the requirements for a midwife to be authorised to deal with the medicines (regulated substances) listed as authorised medicines and immunisation medicines.

A term used in this EPA has the same meaning as the same term used and defined in the *Medicines and Poisons Act 2019* or the MPMR.

Conditions

The following conditions apply to midwives authorised under this EPA, in addition to any conditions and/or restrictions specified in the Appendices.

Give a purchase order

1.1. A midwife who is authorised under this EPA may give *a purchase order* for a medicine listed in Appendix 3 (authorised medicines) or Appendix 4 (immunisation medicines), for the individual midwife to use for a clinical and/or midwifery related service.

Authorised medicines

1.2. A midwife authorised under this EPA must administer and/or give a treatment dose of an authorised medicine listed in Appendix 3, in accordance with the clinical guideline/s stated in Appendix 1 for authorised medicines.

1.3. Before administering or removing a contraceptive subdermal implant or a hormonal intrauterine device, the midwife must:

a. complete the **specified training** stated in Appendix 2 that is applicable to the *scope of medicine dealing* - Administering (insertion) and removing a contraceptive by subdermal implant or a hormonal intrauterine device.

b. hold a current *credentialed defined scope of clinical practice* to administer (insert) and remove a long-acting reversible contraceptive (LARC), that has been granted by the employing Hospital and Health Service or other organisation that provides

Version	Replaces version	Date approved	Commencement date
6	5	30 January 2026	1 March 2026

Queensland Government

a health service, using a credentialing process, including non-formal[1], consistent with -

i. the current *Health Service Directive: Credentialing and defining the scope of clinical practice*, or

ii. the current Australian Commission on Safety and Quality in Health Care *Standard for Credentialing and Defining the Scope of Clinical Practice*.

1.4. Before administering or giving a treatment dose of mifepristone in combination with misoprostol (e.g. MS-2 Step), the midwife must have successfully completed the **specified training** - *early medical termination of pregnancy training*, as detailed in Appendix 2.

1.5. A midwife must not give a treatment dose of a monitored medicine unless stated otherwise in this EPA.

Immunisation medicines

1.6. A midwife who does not meet the immunisation training[2] requirements under Schedule 7, Part 2, Division 2 of the MPMR, is authorised under the EPA to administer an immunisation medicine listed in Appendix 4.

1.7. A midwife must only administer BCG immunisation under the EPA under a tuberculosis immunisation program in accordance with the Health Services Directive – Tuberculosis Control and the Health Service Directive Protocol for the Control of Tuberculosis.

1.8. When immunisation medicines are in the possession of the midwife, the midwife must ensure that the storage and transport of the medicines is in accordance with the National vaccine storage guidelines: Strive for 5.

1.9. Immunisation medicines listed in Appendix 4 must be administered by the midwife in accordance with the clinical guideline/s stated in Appendix 1 for immunisation medicines, in addition to:

a. entering a record that an immunisation medicine has been administered on the Australian Immunisation Register (AIR) as soon as practicable and ideally at the time of immunisation.

b. providing notification of any adverse events occurring following immunisation using the Adverse Event Following Immunisation (AEFI) form published on the Queensland Health website.

[1] Refer to Australian Commission on Safety and Quality in Health Care *Standard for Credentialing and Defining the Scope of Clinical Practice*, page 7, for circumstances when formal credentialing processes may not be required.

[2] Defined under Schedule 22 of the MPMR (with transitional provisions for qualifications or training taken to be immunisation training specified under section 258 of the MPMR)

Appendix 1 – Clinical guidelines

The midwife must undertake any dealings (administer or give as a treatment dose) with medicines listed in the EPA-Midwives, as indicated in the clinical guideline/s stated in the following table for Appendix 3 - Authorised medicines and Appendix 4 – Immunisation medicines.

Medicines	Clinical guideline
Authorised medicines, other than immunisation medicines	Relevant *Queensland Clinical Guidelines* published on the Queensland Health website (https://www.health.qld.gov.au/qcg/publications); OR for relevant organisations, the current online edition of the *Primary Clinical Care Manual*.[3]
Immunisation medicines	For administration of immunisation medicines, including patient selection, patient consent, administration, documenting immunisation and follow up care, the midwife must act in accordance with: a. the current online edition of the *Australian Immunisation Handbook*; or b. the current recommendations issued by the Australian Technical Advisory Group on Immunisation (ATAGI); or c. the product information approved by the Therapeutic Goods Administration (TGA); or d. the current recommendations provided on the *Immunisation Schedule Queensland*.

[3] Unless, in the opinion of the midwife, such actions would be detrimental to the patient. In such instances, an endorsed midwife, medical practitioner or nurse practitioner must be consulted to review the patient.

Appendix 2 – Specified training requirements

Scope of authorised medicine dealing	Specified training	Requirements for specified training
Administer (insert) and remove a contraceptive subdermal implant	*Contraceptive implant insertion and removal training*	A course approved by the midwife's employer that comprises theoretical and simulated training on the insertion, localisation, and removal of *contraceptive implants*, including indications and contraindications, management of common side effects, client counselling and administration of local anaesthetic.
Administer (insert) and remove a contraceptive hormonal intrauterine device	*Hormonal intrauterine device insertion and removal training*	A course approved by the midwife's employer that provides the theoretical and simulated training on the insertion, localisation, and removal of *hormonal intrauterine devices*, including indications and contraindications, management of common side effects and client counselling.
Administer and/or give a treatment dose of mifepristone <u>in combination with</u> misoprostol (e.g. MS-2 Step)	*Early medical termination of pregnancy training*	A course approved by the midwife's employer that includes at a minimum: - education about early medical termination of pregnancy medicine/s including indications, contraindications, management of common side effects and administration; - confirming pregnancy and gestation; - pre and post termination counselling; - cultural safety; - mental health assessment and psychosocial screening; - screening for domestic violence and reproductive coercion; - screening for sexually transmitted infections; - contraceptive advice; - appropriate management; - escalation and follow up.

Appendix 3 – Authorised medicines

Unless otherwise indicated, an authorised medicine listed in Appendix 3 with the symbol ✓ in column 3, may be administered and/or given as a treatment dose by the midwife authorised under this EPA, in accordance with a clinical guideline/s detailed in Appendix 1 for these medicines.

For clarity, **monitored medicines** listed below are indicated by the symbol #.

Schedule 8 (S8) medicines

Regulated substance - medicine	**Approved route of administration**	**Dealing authorised**	**Restrictions/Conditions**
Morphine#	Intramuscular Subcutaneous	Administer only	
Pethidine#	Intramuscular	Administer only	

Schedule 4 (S4) medicines other than immunisation medicines

Regulated substance - medicine	**Approved route of administration**	**Dealing authorised**	**Restrictions/Conditions**
Amoxicillin	Oral	✓	
Amoxicillin/clavulanic acid	Oral	✓	
Anti D (Rh) immunoglobulin	Intramuscular	Administer only	
Azithromycin	Oral	✓	For the treatment of sexually transmitted infecitons.
Benzathine penicillin *e.g. Bicillin L-A*	Intramuscular	Administer only	
Benzatropine	Oral	Administer only	
Benzylpenicillin	Intramuscular Intravenous	Administer only	
Betamethasone	Intramuscular	Administer only	
Cefalexin	Oral	✓	
Ceftriaxone	Intramuscular	Administer only	For the treatment of sexually transmitted infecitons.
Clindamycin	Oral	✓	
Dicloxacillin	Oral	✓	

Regulated substance - medicine	**Approved route of administration**	**Dealing authorised**	**Restrictions/Conditions**
Doxycycline	Oral	✓	For the treatment of sexually transmitted infecitons.
Ergometrine	Intramuscular Intravenous	Administer only	
Etonogestrel *e.g. Implanon*	Subdermal	Administer only	Must have successfully completed the relevant *specified training*.
Flucloxacillin	Oral	✓	
Ibuprofen	Oral	✓	For use as part of the termination of pregnancy protocol.
Levonorgestrel	Oral	✓	
	Intrauterine	Administer only	Must have successfully completed the relevant *specified training*.
Lidocaine 1%	Local infiltration	Administer only	
Lidocaine with adrenaline (epinephrine)	Subcutaneous	Administer only	For the insertion or removal of a contraceptive implant.
Lincomycin	Intramuscular Intravenous	Administer only	
Metoclopramide	Intravenous Intramuscular	Administer only	Adult only.
	Oral	✓	Adult only. May only *give a treatment* dose as part of the termination of pregnancy protocol.
Metronidazole	Oral	✓	For the treatment of sexually transmitted infecitons.
Midazolam[#]	Intravenous Intramuscular Intranasal Buccal	Administer only	

Regulated substance - medicine	**Approved route of administration**	**Dealing authorised**	**Restrictions/Conditions**
Mifepristone and misoprostol *e.g. MS-2 Step*	Oral	✓	Must have successfully completed the relevant *specified training* if dealing with mifepristone in combination with misoprostol (e.g. MS-2 Step).
Misoprostol	Rectal Sublingual Buccal	✓	
Naloxone	Intravenous Intramuscular	Administer only	Neonates only.
Nifedipine	Oral	Administer only	
Nitrofurantoin	Oral	✓	
Nitrous oxide and oxygen	Inhalation	Administer only	
Ondansetron[4]	Oral	✓	
	Intravenous	Administer only	
Oxytocin	Intramuscular Intravenous	Administer only	
Oxytocin / ergometrine	Intramuscular	Administer only	
Paracetamol/Codeine[#]	Oral	✓	For use as part of the termination of pregnancy protocol.
Tranexamic acid	Intravenous	Administer only	
Trimethoprim	Oral	✓	

[4] Use for non-specific nausea and vomiting is off label. Ensure appropriate documentation and evaluation is undertaken as per CATAG guiding principles for the quality use of off label medicines.

Appendix 4 – Immunisation medicines

Regulated substance	Dealing authorised
BCG	Administer
COVID-19	Administer
Diphtheria	Administer
Hepatitis B immunoglobulin-VF (HBIG)	Administer
Hepatitis B	Administer
Influenza	Administer
Measles	Administer
Mumps	Administer
Nirsevimab	Administer
Pertussis	Administer
Respiratory syncytial virus (RSV)	Administer
Rubella	Administer
Tetanus	Administer